CGEN Compugen Ltd Forecast, Technical & Fundamental Analysis
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy... Show more
CGEN is expected to report earnings to -7 cents per share on August 11
Q2'26
Est.
$-0.08
Q1'26
Missed
by $0.01
Q4'25
Beat
by $0.68
Q3'25
Est.
$-0.07
Q2'25
Missed
by $0.02
The last earnings report on May 18 showed earnings per share of -7 cents, missing the estimate of -7 cents. With 118.48K shares outstanding, the current market capitalization sits at 188.77M.
A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with ORMP. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then ORMP could also see price increases.
CGEN in downward trend: price dove below 50-day moving average on June 01, 2026
CGEN moved below its 50-day moving average on June 01, 2026 date and that indicates a change from an upward trend to a downward trend. In of 37 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CGEN as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The 10-day moving average for CGEN crossed bearishly below the 50-day moving average on June 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGEN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CGEN entered a downward trend on June 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CGEN's RSI Oscillator exited the oversold zone, of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CGEN advanced for three days, in of 229 cases, the price rose further within the following month. The odds of a continued upward trend are .
CGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.009) is normal, around the industry mean (18.816). P/E Ratio (5.329) is within average values for comparable stocks, (36.093). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.681). CGEN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (2.630) is also within normal values, averaging (359.668).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CGEN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
